FENNEC PHARMACEUTICALS INC.

Public Equity (NASDAQ)PharmaceuticalsBiotechPublic

📍 Research Triangle Park, NC, United States• Founded 1996

StreetZero Signal 58

Be the first to signal interest

About FENNEC PHARMACEUTICALS INC.

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the development of Sodium Thiosulfate for the prevention of cisplatin-induced hearing loss, or ototoxicity, in children. Its product candidate is PEDMARK, a novel formulation of sodium thiosulfate. The company principally operates in the United States as a specialty pharmaceutical company and is publicly traded on NASDAQ (FENC) and TSX (FRX).

LATEST FUNDINGRule 144

$240K

Announced 2026-11-13

TOTAL RAISED$148.55M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for FENNEC PHARMACEUTICALS INC..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED1996

HQResearch Triangle Park, NC, United States

Industry

Public Equity (NASDAQ)

Investors

Petrichor Healthcare Capital Management HBM Healthcare Investments Oregon Health & Science University

Key highlights

Completed underwritten public offering of over 5.3 million common shares in November 2025.
Redeemed all outstanding convertible notes held by Petrichor entities, resulting in zero debt.
Product candidate PEDMARK targets prevention of cisplatin-induced ototoxicity in children.
Listed on NASDAQ Capital Market since 2017, enhancing visibility and liquidity.
Total funding across 10 rounds reached 148.55M USD with institutional healthcare investors.